why choose us

First received: September 01, 2022

Clinical Trial: Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Non-randomized, Open-label, and Dose-escalation Phase I Study to Evaluate the Safety of Prodencel Treatment in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Brief Summary: This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Read more